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Abstract: Tuberculosis (TB) is the only opportunistic infection,
which is transmissible to the healthy immunocompetent host. HIV
is the most important known risk factor that promotes progression
to active TB in people with Mycobacterium tuberculosis infection.
The lifetime risk of tuberculosis in immunocompetent persons is
5% to 10%, but in HIV positive patients, there is a 5% to 15% annual
risk of developing active TB disease. During the past two decades,
TB has become the major opportunistic infection complicating the
HIV epidemic worldwide, especially in Asia and Africa.
India has one of the world’s highest burdens of both TB (∼2.1
million cases annually) and HIV infection (2.3 million prevalent
cases). While TB occurs in all socioeconomic strata and ethnic
groups, prevalence rates have been clearly linked to poverty. It has
been estimated that undernutrition, HIV, smoking and diabetes are
all strong risk factors for TB.Maternal TB in anHIV-infectedwoman
is a risk factor for transmission of HIV to the infant and is associ-
ated with premature delivery or low-birth weight and with higher
maternal and infant mortality.
Patients with advanced immunodeﬁciency are at high risk for
acquisition of Rifampicin resistance when treated with twice-
weekly or thrice-weekly regimens. This is possibly due to
malabsorption and low blood levels of anti-TB drugs. Cure rates
with standard anti-TB treatment regimens average 86%, but out-
comes in HIV-infected individuals are worse than uninfected
patients. Though most HIV-infected patients respond well to anti-
tuberculosis treatment (ATT) initially, there is a signiﬁcant risk of
developing other opportunistic infections as well as recurrent TB,
leading to increased mortality. Timely initiation of antiretroviral
therapy (ART) has been shown to reduce mortality and improve
long-term outcome of these patients. Several trials have now
shown that early initiation of ART (within the ﬁrst few weeks of
ATT) reduces mortality and improves TB outcomes. The choice of
ART regimen is governed by the drug-drug interactions between
anti-TB and antiretroviral drugs: rifampicin is an inducer of the
cytochrome p450 enzyme system, which metabolizes NNRTI drugs
nevirapine and efavirenz. The metabolism of the latter is less
affected by rifampicin and hence efavirenz is the NNRTI of choice
when combined with ATT.
The 4 “I” policy for addressing co-infection of TB and HIV
includes intensiﬁed case ﬁnding, infection control, isoniazid pre-
ventive chemotherapy and integration of TB and HIV services
within antenatal, PMTCT, family planning and immunization ser-
vices. Since HIV has become a chronic, manageable condition, the
challenge ahead is to provide services to patients in an integrated
manner and strengthen health systems so that long-term care can
be effectively provided. Research priorities include improved and
more sensitive point of care diagnostics for TB, shorter and more
effective TB treatment regimens with minimum drug interactions
with antiretroviral drugs and a better TB vaccine that is safe and
effective in HIV-infected populations.
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Abstract: In sub-Saharan Africa, despite successful scale-up of
ART programmes, opportunistic infections remain a frequent cause
of morbidity, hospitalization and death. Factors that contributed
to this are delays to HIV diagnosis, late engagement in ART care,
difﬁculties with ART adherence and many patients not remaining
engaged in care. Although tuberculosis is themost frequent HIV co-
infection in the region, other opportunistic infections also result in
considerable morbidity and mortality.
The main focus of this presentation will be cryptococcal menin-
gitis. National surveillance data from South Africa show that
6000-8000 cases of cryptococcosis have been diagnosed annually
over the last decade. Case fatality rates remain extremelyhigh,with
around two-thirds of patients dying or being lost to follow-up in
routine clinical settings and one-third in clinical trial settings. In
terms of management, a randomized controlled trial conducted
in Vietnam demonstrated that the induction antifungal therapy
associated with the best survival was a combination of ampho-
tericin B with ﬂucytosine for 2 weeks. Flucytosine access is limited
in sub-Saharan African countries, but this is being addressed by
advocacy initiatives. Sertraline has anti-cryptococcal activity and
is currently being evaluated as an addition to combination ther-
apy. Over 60% of patients have raised intracranial pressure; this is
managedwith serial therapeutic lumbar punctures. Unlike TB, very
early ART has been shown to increase mortality in patients with
cryptococcal meningitis: in the Cryptococcal Optimal ART Timing
